New hope for advanced liver cancer: phase 3 trial tests aggressive treatment combinations
NCT ID NCT06172205
Summary
This Phase 3 trial compares two combination treatments for advanced liver cancer that has spread. One approach uses standard intravenous chemotherapy plus immunotherapy and targeted therapy. The other delivers chemotherapy directly to the liver through an artery before adding the same drugs. Researchers want to see which approach better controls cancer growth and extends survival for 262 participants with advanced liver cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCLC STAGE C HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.